A Phase 3 interventional study of Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) and r-hFSH in Reproductive Techniques, Assisted, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present study was designed to investigate, in hyporesponder subjects, that required in a previous assisted reproductive technologies (ART) cycle follicle stimulating hormone (FSH) >3500 International Unit (IU), the possibility to decrease through recombinant human luteinizing hormone (r-hLH) supplementation, the FSH amount per oocytes retrieved and in the mean time to improve the overall cycle outcome.
Recombinant human follicle stimulating hormone (r-hFSH), which totally lacks LH activity, is widely used to induce multiple follicle development in women under pituitary desensitization, in order to submit them to treatment with assisted reproduction techniques (ART). Clinical experience from hypogonadotropic-hypogonadic women suggests that while FSH alone is sufficient to induce follicle development, LH plays a significant part in final follicle maturation, estrogen synthesis and optimal endometrium growth.
This was a phase III, multicentre, randomized, open-label comparative study to evaluate if the addition of r-hLH (Luveris) in a 2:1 ratio to FSH from day 8 of ovarian stimulation is able to decrease the total FSH dose and to improve cycle outcome in 250 infertile women undergoing ART, who required high FSH dose in a previous cycle (≥ 3500 IU). Subjects who have met all the inclusion criteria, achieved pituitary desensitization and started controlled ovarian hyperstimulation (COH) treatment with FSH, on stimulation day 8 (S8) received an identification number and will be allocated to one of the two following arms:
Arm : FSH + r-hLH (2:1 ratio of FSH:r-hLH), Arm : FSH alone. Treatment with Luveris was commenced on day 8 (S8) and continued until injection of hCG or cancellation of the treatment cycle.
Monitoring of stimulation, FSH dose escalation, criteria for injection of hCG, ovum pick up, embryo transfer and pregnancy confirmation took place according to standard management practice. The in-vitro fertilization (IVF) or intracytosolic sperm injection (ICSI) procedure, including luteal phase support, was performed according to each centres' normal procedures.
The subjects were followed up and the treatment outcome (menstruation or pregnancy) was recorded. The delivery outcome for any pregnant subjects was recorded in the Case Report Form (CRF).
Information on the delivery outcome for each pregnancy was collected. Information on adverse events was collected during the study period.
OBJECTIVES
The primary objective of the study was:
To determine whether the addition of r-hLH (Luveris) from day 8 of ovarian stimulation reduces the FSH dose needed to obtain/retrieve each oocyte.
The secondary objectives of the study were:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
Drug: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)
Subjects treated with r-hFSH alone
Drug: r-hFSH
Drug page: Follitropin alfa
One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
Also known as: r-hLH, r-hFSH
One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes
Time frame: Baseline (Stimulation day 8 [S8]) until hCG day
Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose
Time frame: Baseline (S8) until hCG day
Mean Number of Ovarian Stimulation Days
Time frame: Baseline (S8) until hCG day
Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day
Time frame: Baseline (S8) and hCG day
Mean Total Number of Retrieved Oocytes
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: 34-36 hours post-hCG (OPU)
Mean Number of Mature Oocytes (Metaphase II)
Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.
Time frame: 34-36 hours post-hCG (OPU)
Fertilization Rate
Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).
Time frame: 12-18 day post-hCG and/or Week 7
Number of Obtained Embryos
Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.
Time frame: Day 3 post-hCG (Embryo transfer [ET])
Number of Transferred Embryos
Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.
Time frame: Day 3 post-hCG (ET)
Percentage of Participants With Pregnancy
Time frame: 12-18 day post-hCG and/or Week 7
Percentage of Participants With Clinical Pregnancy
Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
Time frame: 12-18 day post-hCG and/or Week 7
Percentage of Participants With Implantation
Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.
Time frame: 12-18 day post-hCG and/or Week 7
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.
Time frame: Baseline (S8) until 12-18 day post-hCG and/or Week 7
Number of Cycles Cancelled Due to Risk of OHSS
OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.
Time frame: Baseline (S8) until 12-18 day post-hCG and/or Week 7
| Milestone | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Started | 67 | 66 |
| Completed | 60 | 63 |
| Not completed | 7 | 3 |
| Withdrew: Lack of ovarian response | 1 | 1 |
| Withdrew: No fertilization | 4 | 0 |
| Withdrew: No oocytes retrieved | 1 | 1 |
| Withdrew: Ovarian hyper stimulation syndrome | 1 | 0 |
| Withdrew: No viable embryos | 0 | 1 |
| IU | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Baseline (S8) | 904.6 ± 1068.1 | 703.3 ± 924.5 |
| Baseline (S8) until hCG day | 388.5 ± 631.3 | 318.5 ± 534.0 |
| IU | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Total FSH dose | 1434.0 ± 678.1 | 1595.0 ± 796.4 |
| Total r-hLH dose | 575.9 ± 273.0 | 0 ± 0 |
| Days | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Mean Number of Ovarian Stimulation Days | 4.6 (2.0 to 10.0) | 4.8 (1.0 to 9.0) |
| picogram/milliter (pg/mL) | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Baseline (n = 59,59) | 516.1 ± 353.6 | 518.9 ± 334.2 |
| Change at hCG day (n = 40,47) | 1391.6 ± 743.4 | 1179.9 ± 746.5 |
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
| oocytes | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Mean Total Number of Retrieved Oocytes | 7.0 ± 4.6 | 7.8 ± 3.9 |
Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.
| Metaphase II Oocytes | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Mean Number of Mature Oocytes (Metaphase II) | 5.1 ± 3.7 | 5.7 ± 3.2 |
Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).
| ratio | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Fertilization Rate | 0.85 ± 0.29 | 0.89 ± 0.20 |
Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.
| embryos | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Number of Obtained Embryos | 142 | 158 |
Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.
| embryos | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Number of Transferred Embryos | 60 | 63 |
| percentage of participants | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Percentage of Participants With Pregnancy | 29.9 | 30.8 |
Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
| percentage of participants | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Percentage of Participants With Clinical Pregnancy | 23.9 | 18.5 |
Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.
| percentage of participants | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Percentage of Participants With Implantation | 13.38 | 11.39 |
OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.
| participants | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Mild OHSS | 0 | 0 |
| Moderate OHSS | 1 | 0 |
| Severe OHSS | 0 | 0 |
OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.
| cycles | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Number of Cycles Cancelled Due to Risk of OHSS | 1 | 0 |
Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 12-18 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FSH + rhLH | — | 1/67 (1.5%) | 2/67 (3%) |
| Follicle-stimulating Hormone (FSH) | — | 2/66 (3%) | 0/66 (0%) |
| Event | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Left ectopic pregnancyGeneral disorders | 0/67 | 1/66 |
| Renal colicGeneral disorders | 0/67 | 1/66 |
| CerclageGeneral disorders | 1/67 | 0/66 |
| Event | FSH + rhLH | Follicle-stimulating Hormone (FSH) |
|---|---|---|
| Ovarian Hyper Stimulation SyndromeGeneral disorders | 1/67 | 0/66 |
| Urticaria post intake of food (fish)General disorders | 1/67 | 0/66 |
| Age, Continuous(years) | FSH + rhLH | Follicle-stimulating Hormone (FSH) | Total |
|---|---|---|---|
| Mean | 35.6 ± 2.9 | 35.0 ± 3.8 | 35.3 ± 3.4 |
| Sex: Female, Male(Participants) | FSH + rhLH | Follicle-stimulating Hormone (FSH) | Total |
|---|---|---|---|
| Female | 67 | 66 | 133 |
| Male | 0 | 0 | 0 |
The record gives a start of Mar 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Helping Behavior
Merck KGaA, Darmstadt, Germany →